Canada’s Intellectual Property Firm

CADTH Common Drug Review to accept submissions up to six months prior to market approval

The Canadian Agency for Drugs and Technologies in Health (CADTH) announced on March 8, 2018 that, effective April 2, 2018, its Common Drug Review (CDR) program will accept drug submissions up to six months prior to a drug manufacturer’s anticipated receipt of a Notice of Compliance (NOC) or NOC with Conditions (NOC/c) from Health Canada. This will be earlier than the present three-month deadline. Additional details regarding this operational change can be found in CDR Update – Issue 134.